4.6 Article

Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma

期刊

FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.767644

关键词

hepatocellular carcinoma; TRIM family; signature; prognosis; LASSO

类别

资金

  1. National Natural Science Foundation of China [81772964, 81974448, 82073066]
  2. President Foundation of Nanfang Hospital, Southern Medical University [2020C005]
  3. National Major New Drug Creation Science and Technology Major Special Fund Funding Project [2020ZX09201017]
  4. Guangdong gastrointestinal disease research center [2017B020209003]
  5. Special Scientific Research Fund of Public Welfare Profession of National Health and Family Planning Commission [201502026]
  6. Shenzhen Science and Technology Innovation Commission [JCYJ20180306170328854, JCYJ20210324135005013]

向作者/读者索取更多资源

The study identified the potential application values of the TRIM family for outcome prediction in HCC. A novel TRIM family gene-based signature was built for predicting overall survival in HCC, showing good performance in prediction. High expressions of certain TRIM family members were significantly associated with poor overall survival in HCC patients.
Background: Accumulating studies have demonstrated the abnormal expressions and prognostic values of certain members of the tripartite motif (TRIM) family in diverse cancers. However, comprehensive prognostic values of the TRIM family in hepatocellular carcinoma (HCC) are yet to be clearly defined. Methods: The prognostic values of the TRIM family were evaluated by survival analysis and univariate Cox regression analysis based on gene expression data and clinical data of HCC from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The expression profiles, protein-protein interaction among the TRIM family, prediction of transcription factors (TFs) or miRNAs, genetic alterations, correlations with the hallmarks of cancer and immune infiltrates, and pathway enrichment analysis were explored by multiple public databases. Further, a TRIM family gene-based signature for predicting overall survival (OS) in HCC was built by using the least absolute shrinkage and selection operator (LASSO) regression. TCGA-Liver Hepatocellular Carcinoma (LIHC) cohort was used as the training set, and GSE76427 was used for external validation. Time-dependent receiver operating characteristic (ROC) and survival analysis were used to estimate the signature. Finally, a nomogram combining the TRIM family risk score and clinical parameters was established. Results: High expressions of TRIM family members including TRIM3, TRIM5, MID1, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, and TRIM72 were significantly associated with HCC patients' poor OS. A novel TRIM family gene-based signature (including TRIM5, MID1, TRIM21, TRIM32, TRIM44, and TRIM47) was built for OS prediction in HCC. ROC curves suggested the signature's good performance in OS prediction. HCC patients in the high-risk group had poorer OS than the low-risk patients based on the signature. A nomogram integrating the TRIM family risk score, age, and TNM stage was established. The ROC curves suggested that the signature presented better discrimination than the similar model without the TRIM family risk score. Conclusion: Our study identified the potential application values of the TRIM family for outcome prediction in HCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据